Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

Alberto Ocana; Atanasio Pandiella

doi:10.18632/oncotarget.14731

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

Alberto Ocana _ and Atanasio Pandiella

PDF | HTML | How to cite

Oncotarget. 2017; 8:22218-22234. https://doi.org/10.18632/oncotarget.14731

Metrics: PDF 2488 views | HTML 6480 views | ?

Abstract

Alberto Ocana1 and Atanasio Pandiella2

1 Unidad de Investigación Traslacional, Hospital Universitario de Albacete, Universidad de Castilla La Mancha, Albacete, Spain

2 Instituto de Biología Molecular y Celular del Cáncer and CIBERONC. CSIC-Universidad de Salamanca, Salamanca, Spain

Correspondence to:

Alberto Ocana, email:

Keywords: triple negative breast cancer, breast cancer, kinases, novel therapies

Received: December 12, 2016 Accepted: January 11, 2017 Published: January 18, 2017

Abstract

Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this article, we review the biological bases of this entity and how the known molecular evidence supports the current preclinical and clinical development of new therapies. Special attention will be given to ongoing clinical studies and potential options for future drug combinations.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14731

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies

Abstract